An open-label, randomized, single-center, 2-way cross-over interaction study, evaluating the effect of esomeprazole 20 mg/acetylsalicylic acid 81 mg on the pharmacodynamics and the pharmacokinetics of clopidogrel on days 1 and 9 in healthy volunteers

Trial Profile

An open-label, randomized, single-center, 2-way cross-over interaction study, evaluating the effect of esomeprazole 20 mg/acetylsalicylic acid 81 mg on the pharmacodynamics and the pharmacokinetics of clopidogrel on days 1 and 9 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Apr 2014

At a glance

  • Drugs Aspirin/esomeprazole (Primary) ; Clopidogrel
  • Indications Cardiovascular disorders; NSAID-induced ulcer
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 28 Mar 2014 Results published in the American Journal of Cardiovascular Drugs.
    • 06 Oct 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 06 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top